Design and synthesis of novel phthalazinone derivatives as potent poly(ADP-ribose)polymerase 1 inhibitors.

Aim: The development of effective PARP-1 inhibitors has received great enthusiasm in medicinal chemistry communities. Results: A new series of novel phthalazinone derivatives were designed and synthesized. Among these, B1 and B16 displayed more potent PARP-1 inhibitory activities than olaparib. B16 gave an IC50 value of 7.8 nM against PARP-1, and a PF50 value of 3.4 in the sensitizing effect assay. The in vivo pharmacokinetic properties evaluation showed B16 displayed insufficient oral exposure, and it was also not stable in rat blood. Conclusion: The results indicated that our design phthalazinone derivatives were potent PARP-1 inhibitors, and compound B16 was a valuable lead compound with siginificant in vitro efficacy, deseaving further optimization so as to develop anticancer drug candidate.

[1]  C. Walsh.  Latest clinical evidence of maintenance therapy in ovarian cancer. , 2019, Current opinion in obstetrics & gynecology.

[2]  A. Zheng,et al.  Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors. , 2019, European journal of medicinal chemistry.

[3]  Yifan Feng,et al.  Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors. , 2019, Bioorganic & medicinal chemistry.

[4]  B. Golding.  The Story of Rucaparib (Rubraca) , 2019, Successful Drug Discovery.

[5]  Joon-Oh Park,et al.  Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. , 2019, The New England journal of medicine.

[6]  Xiaoguang Chen,et al.  Discovery of quinazoline-2,4(1H,3H)-dione derivatives as novel PARP-1/2 inhibitors: design, synthesis and their antitumor activity. , 2018, Organic & biomolecular chemistry.

[7]  S. Snyder,et al.  Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases , 2018, British journal of pharmacology.

[8]  W. Kraus,et al.  PARP Inhibitors for Cancer Therapy , 2017, Cell.

[9]  Asher Mullard.  FDA approves Novartis's CDK4/6 inhibitor , 2017, Nature Reviews Drug Discovery.

[10]  Alan Ashworth,et al.  PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.

[11]  Yuyang Jiang,et al.  PARP inhibitors as antitumor agents: a patent update (2013-2015) , 2017, Expert opinion on therapeutic patents.

[12]  Bohdan Waszkowycz,et al.  First-in-Class Chemical Probes against Poly(ADP-ribose) Glycohydrolase (PARG) Inhibit DNA Repair with Differential Pharmacology to Olaparib. , 2016, ACS chemical biology.

[13]  Z. Miao,et al.  An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy. , 2016, Journal of medicinal chemistry.

[14]  Feng Tang,et al.  The discovery of novel N-(2-pyrimidinylamino) benzamide derivatives as potent hedgehog signaling pathway inhibitors. , 2013, Bioorganic & medicinal chemistry letters.

[15]  金秋,et al.  苯并呋喃类聚腺苷二磷酸核糖聚合酶(PARP)抑制剂的设计、合成及活性研究 , 2013 .

[16]  V. Schreiber,et al.  The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. , 2012, Biochemical pharmacology.

[17]  Krystyna J. Dillon,et al.  Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase. , 2005, Bioorganic & medicinal chemistry letters.

[18]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[19]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[20]  N. Curtin,et al.  Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase. , 2004, Journal of medicinal chemistry.

[21]  P. Hergenrother,et al.  An enzymatic assay for poly(ADP-ribose) polymerase-1 (PARP-1) via the chemical quantitation of NAD(+): application to the high-throughput screening of small molecules as potential inhibitors. , 2004, Analytical biochemistry.

[22]  C. Szabó,et al.  The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors , 2002, Pharmacological Reviews.